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D-Cycloserine (DCS) targets the peptidoglycan biosynthetic enzymes D-alanine racemase (Alr) and D-
alanine:D-alanine ligase (Ddl). Previously, we demonstrated that the overproduction of Alr in Mycobacterium
smegmatis determines a DCS resistance phenotype. In this study, we investigated the roles of both Alr and Ddl
in the mechanisms of action of and resistance to DCS in M. smegmatis. We found that the overexpression of
either the M. smegmatis or the Mycobacterium tuberculosis ddl gene in M. smegmatis confers resistance to DCS,
but at lower levels than the overexpression of the alr gene. Furthermore, a strain overexpressing both the alr
and ddl genes displayed an eightfold-higher level of resistance. To test the hypothesis that inhibition of Alr by
DCS decreases the intracellular pool of D-alanine, we determined the alanine pools in M. smegmatis wild-type
and recombinant strains with or without DCS treatment. Alr-overproducing strain GPM14 cells not exposed
to DCS displayed almost equimolar amounts of L- and D-alanine in the steady state. The wild-type strain and
Ddl-overproducing strains contained a twofold excess of L- over D-alanine. In all strains, DCS treatment led to
a significant accumulation of L-alanine and a concomitant decease of D-alanine, with approximately a 20-fold
excess of L-alanine in the Ddl-overproducing strains. These data suggest that Ddl is not significantly inhibited
by DCS at concentrations that inhibit Alr. This study is of significance for the identification of the lethal
target(s) of DCS and the development of novel drugs targeting the D-alanine branch of mycobacterial pepti-
doglycan biosynthesis.
The bacterial cell wall is an ideal target for drug design since
similar structures and biosynthetic pathways are absent from
mammalian hosts. The lipid-rich mycobacterial cell wall acts as
an efficient permeability barrier (4). Peptidoglycan, the back-
bone of this structure, contains the D-amino acids D-alanine,
D-glutamate, and diaminopimelate, which may contribute to its
stability against proteolytic degradation. D-Alanine is one of
the central molecules of the cross-linking step of peptidoglycan
assembly. Peptidoglycan biosynthesis in mycobacteria follows
pathways similar to those in other eubacteria (2). There are
three enzymes involved in the D-alanine branch of peptidogly-
can biosynthesis: the pyridoxal phosphate-dependent D-alanine
racemase (Alr), the ATP-dependent D-alanine:D-alanine ligase
(Ddl), and the ATP-dependent D-alanine:D-alanine-adding en-
zyme (MurF) (32). D-Cycloserine (DCS; 4-amino-3-isoxazo-
lidinone) is a rigid analog of D-alanine and targets both Alr and
Ddl in Escherichia coli (16, 19). DCS also inhibits Mycobacte-
rium tuberculosis Alr and Ddl enzymes (9, 28), suggesting that
both Alr and Ddl are targets of DCS in mycobacteria.
DCS is effective against mycobacteria and is recommended
to treat multidrug-resistant M. tuberculosis in the DOTS-Plus
management plan (13, 35). However, undesirable side effects
restrict its use in human chemotherapy (36). Nonetheless, the
potent bactericidal effect of DCS against mycobacteria makes
this drug an attractive prototype compound to develop novel
antimycobacterial agents. In addition, identification of the le-
thal target(s) of DCS action would allow for the rational design
of new antimycobacterial drugs, structurally related or unre-
lated to DCS, targeting enzymes of the D-alanine pathway of
peptidoglycan biosynthesis. Moreover, this type of inhibitors
may weaken the cell wall and act synergistically with other
antimicrobial agents (21). In the early 1970s, David (8) isolated
and characterized step-wise DCS-resistant M. tuberculosis mu-
tants that showed either normal or reduced cellular permeabil-
ity to DCS and speculated that Alr plays only a minor role in
the mechanism of action of DCS. Mycobacterium smegmatis, a
nonpathogenic species, is a useful model to study drug resis-
tance mechanisms in pathogenic mycobacteria, especially when
conserved cellular processes are involved (23, 31). Peteroy et
al. (20) described the isolation and characterization of an M.
smegmatis mutant resistant to both DCS and vancomycin
though the molecular basis of the resistance mechanism re-
mains unknown. In our studies, a spontaneous DCS-resistant
M. smegmatis mutant with a promoter-up mutation in the alr
gene, resulting in the overproduction of the Alr enzyme, was
identified (5). Alr was shown to be inhibited by DCS in a
concentration-dependent manner, and DCS resistance could
be conferred to pathogenic mycobacteria carrying the M. smeg-
matis alr gene in a multicopy plasmid. In addition, DCS was
shown to competitively inhibit the native Ddl enzyme from M.
tuberculosis (9). Belanger et al. (3) reported the characteriza-
tion of a temperature-sensitive M. smegmatis mutant with a
single amino acid substitution in Ddl. The mutant was more
susceptible to DCS, and the temperature sensitivity phenotype
was due to the decreased activity of the mutated enzyme.
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Recently, we observed that M. smegmatis alr null mutants are
not dependent on D-alanine for growth, suggesting the exis-
tence of another pathway for D-alanine biosynthesis (6). In
addition, the alr null mutant is hypersusceptible to DCS, sug-
gesting that a lethal target other than Alr is responsible for the
bactericidal effect of DCS.
In this study, we investigated the roles of both Alr and Ddl
in the mechanisms of action of and resistance to DCS in M.
smegmatis. We demonstrate that Ddl activity is inhibited by
DCS in a concentration-dependent manner. Overexpression of
the ddl gene confers resistance to DCS but not to -chloro-D-
alanine (CDA), an inhibitor of D-alanine racemase. Further-
more, a strain overexpressing both the alr and ddl genes dis-
played an increased level of resistance to DCS. Analysis of the
intracellular alanine pools in wild-type and recombinant M.
smegmatis strains suggested that Ddl activity is not significantly
affected by DCS at concentrations inhibiting Alr.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. Bacterial strains and plas-
mids used in this study are listed in Table 1. E. coli strains were grown at 37°C
in Luria-Bertani broth or agar. M. smegmatis strains were grown at 37°C with
shaking (200 rpm; Innova 4300 incubator shaker; New Brunswick Scientific,
Edism, N.J.) in Middlebrook 7H9 broth (BBL Microbiology Systems, Cock-
eysville, Md.) supplemented with albumin-dextrose complex (ADC) and 0.05%
Tween 80 (M-ADC-TW broth). For analysis of the intracellular amino acid
pools, M. smegmatis was grown in a minimal medium based on the formulation
of Zygmunt (37) and modified as previously described (6). Tryptic soy agar base
(Difco Laboratories, Detroit, Mich.) was used for growth of M. smegmatis on
solid media. Transformations of E. coli and M. smegmatis were performed by
electroporation with a Gene Pulser (Bio-Rad Laboratories, Richmond, Calif.) as
described previously (14). The following antibiotics were added to the media
when necessary: kanamycin (Sigma Chemical Co., St. Louis, Mo.) at 50 g ml1
or carbenicillin (Sigma) at 50 g ml1 for E. coli strains and kanamycin at 10 g
ml1 for M. smegmatis strains.
Oligonucleotide primers, nucleic acid manipulations, and primer extension
analysis. The oligonucleotide primers (Integrated DNA Technologies, Inc., Cor-
alville, Iowa) for PCR amplification of the complete ddl gene from M. smegmatis
were SMDDLCF (5-CGC ATA AGG CCA GGT CAG-3) and SMDDLCR
(5-CGA AAA ACC CGT CGT GC-3). The primers for PCR amplification of
the ddl gene from M. tuberculosis were DDLATBU (5-GCT AAG TGC CGA
TCG CAA G-3) and DDLATBD (5-ATA ACG CTG CTG CTG GGT C-3)
and TBDDLEXF (5-CGG GAT CCG TGA GTG CTA ACG AC-3) and
TBDDLEXR (5-CGG AAG CTT GTG CCG ATC GCA AGC-3). The primers
SMDDLPE (5-AAA CGC TCC GGA TCG AGG TTG-3) and TBDDLPE
(5-GAG ATG GCG TGC TCG TTG-3) were used in primer extension analysis
for the ddl mRNA of M. smegmatis and M. tuberculosis, respectively. PCR
amplifications were performed in a Perkin-Elmer GeneAmp 9600 thermal cycler
(Roche Molecular Systems, Branchburg, N.J.) by using the Expand high-fidelity
PCR system (Roche Molecular Biochemicals, Indianapolis, Ind.). For restriction
digestions, ligations, and agarose gel electrophoresis, standard procedures pre-
viously described (24) were followed. Total RNA from M. smegmatis strains was
isolated by using RNAWIZ (Ambion, Inc., Austin, Tex.) with minor modifica-
tions (1). Primer extension analysis of the ddl mRNA was carried out as de-
scribed previously (11). The oligonucleotide was radiolabeled with [-32P]ATP
by using T4 polynucleotide kinase (Promega, Madison, Wis.), and the reactions
were extended with Moloney murine leukemia virus reverse transcriptase (Pro-
mega). Radioactivity in primer extension products was quantified with a Phos-
phorImager by using ImageQuant, version 3.3 (Molecular Dynamics, Sunnyvale,
Calif.).
M. smegmatis genomic library construction and cloning of the M. smegmatis ddl
gene. Chromosomal DNA from M. smegmatis mc2155 was prepared as described
previously (33). For library construction, chromosomal DNA was partially di-
gested with Sau3AI, and fragments of 3.0 to 4.0 kb were purified from 0.8%
agarose. This fraction was ligated with the E. coli-Mycobacterium shuttle plasmid
pMV262 (7), linearized with BamHI, and dephosphorylated. The ligation mix-
ture was transformed into E. coli XL10-GOLD (Stratagene, La Jolla, Calif.), and
approximately 6,000 recombinants were obtained for a theoretical representation
of P as 99% of the M. smegmatis genome.
A recombinant clone carrying the M. smegmatis ddl gene was identified from
a genomic library by colony hybridization using a species-specific probe. An
internal fragment of the M. smegmatis ddl gene was amplified by PCR using a
pair of degenerate primers, DDLF and DDLR, based on two signature peptides
of bacterial Ddl enzymes (12). This amplified fragment was verified and radio-
labeled with the Rediprime II labeling system (Amersham Pharmacia Biotech,
Piscataway, N.J.). For screening the library, about 10,000 colonies from the
library pool were plated, transferred to the NYTRAN nylon membrane (Mid-
west Scientific, Valley Park, Mo.), and screened with the labeled probe as de-
scribed previously (24). After three rounds of screening, the recombinant plas-
mid pBUN172 was identified and confirmed to contain the full-length ddl gene.
This sequence is identical to the sequence at GenBank with accession no.
AF077728 (3) and the sequence from the unfinished M. smegmatis mc2155
genome (http://www.tigr.org).
Drug susceptibility assays. MICs were determined by a microdilution method
described previously (29) with minor modifications. Briefly, M. smegmatis cells
were grown in M-ADC-TW to mid-exponential phase (optical density at 600 nm,
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Description Reference and/orsource
E. coli XL10-GOLD Tetr (mcrA)183 (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96
relA1 lac Hte [F proAB laclqZM15 Tn10 (Tetr) Amy Camr]
Stratagene
M. smegmatis mc2155 High-transformation M. smegmatis mutant derived from mc26 25
M. smegmatis GPM2 mc2155(pMV262) 5
M. smegmatis GPM14 DCS-resistant mutant derived from mc2155; overproducing Alr 5
M. smegmatis GPM259 mc2155(pBUN250); overproducing Ddl This work
M. smegmatis GPM260 GPM14(pBUN250); overproducing both Alr and Ddl This work
M. smegmatis GPM265 mc2155(pBUN276); overproducing M. tuberculosis Ddl This work
M. smegmatis GPM198A mc2155(pBUN128A) This work
pCR2.1 TA cloning vector Invitrogen
pMV262 E. coli-Mycobacterium shuttle plasmid MedImmune, Inc.; 7
pBUN128A pMV262 with a 1.4-kb insert containing the complete M. tuberculosis ddl gene
inserted at the EcoRI site
This work
pBUN172 Recombinant plasmid isolated from an M. smegmatis genomic library which
hybridized with an internal fragment of the ddl gene
This work
pBUN250 pMV262 with a 1.4-kb insert containing the complete M. smegmatis ddl gene
inserted at the EcoRI site
This work
pBUN276 pMV262 with the M. tuberculosis ddl gene inserted at the BamHI/HindIII
site; the M. tuberculosis ddl gene is fused with the DNA sequence
corresponding to the first 6 codons of the M. bovis BCG hsp60 gene
This work
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0.6 to 1.0). Approximately 105 CFU in 0.1 ml were inoculated in triplicate onto
96-well microplates containing serial twofold dilutions of inhibitory compounds.
Plates were incubated at 37°C and examined daily. The MIC was defined as the
minimal concentration of the drug or inhibitor that prevented visible bacterial
growth after 48 h. Each MIC represents the consistent result from at least three
independent cultures. Amikacin, DCS, CDA, ethambutol, and vancomycin (all
from Sigma) were prepared in sterile deionized water. Rifabutin (Amersham
Pharmacia) was prepared in dimethyl sulfoxide (Fisher Scientific, St. Louis,
Mo.). All further dilutions of each antibiotic were prepared in growth medium.
Inhibition of colony formation by DCS was evaluated as described previously (5).
Appropriate dilutions of exponentially growing M. smegmatis cells were plated
onto agar containing 0 to 1,200 g of DCS ml1. Colonies were counted after 5
days of incubation at 37°C. Statistical analysis was conducted using the SAS
general linear model procedure (SAS Institute, Cary, N.C.).
Preparation of crude cell extracts from M. smegmatis strains. M. smegmatis
cells were harvested at exponential phase and concentrated 50-fold in ice-cold 50
mM Tris-HCl (pH 8.0). Cells were disrupted with a French pressure cell
(Thermo Spectronic US, Rochester, N.Y.) at 14,000 lb/in2. The lysate was cen-
trifuged at 4°C for 30 min at 30,000 	 g to remove cell debris. The supernatant
was subjected to ultracentrifugation at 4°C for 4 h at 110,000 	 g to remove the
membrane fraction. The recovered supernatant was dialyzed twice against 50
mM Tris-HCl (pH 8.0) at 4°C and sterilized by filtration through 0.22-m-pore-
size filters. The protein concentration was determined by using the DC protein
assay (Bio-Rad) as recommended by the manufacturer.
Enzyme assays. The crude extract was assayed for Ddl activity by a modified
thin-layer chromatography (TLC)-based method described previously (18). This
procedure can quantitatively determine the amount of D-alanine:D-alanine
dipeptide. Briefly, crude extracts (5 to 30 g of total protein) were incubated at
37°C for 4 h in a 50-l final volume containing 50 mM Tris-HCl (pH 7.8), 10 mM
MgCl2, 10 mM KCl, 50 mM unlabeled D-alanine, 6 mM ATP, 2.5 mM glutathi-
one, and 5.0 Ci of [1-14C]D-alanine (100 Ci/ml; ICN Biochemicals, Inc., Costa
Mesa, Calif.). For inhibition assays, DCS was added to the final concentrations
of 50, 100, 200, 400, and 800 g ml1. Subsequently, 10 l of the reaction mixture
was applied to cellulose-backed TLC plates (Sigma), and ascending chromatog-
raphy was developed in n-butanol–acetic acid–water (12:3:5) until the solvent
reached the top of the TLC plate. The plate was dried at 100°C for 5 min, and
the radioactivity corresponding to the position of the D-alanine and D-alanine:
D-alanine dipeptide was measured with a PhosphorImager. Specific activity was
calculated as micromoles of D-alanine consumed per milligram per minute. The
alanine racemase activity was measured in the direction of the conversion of
L-alanine to D-alanine by a coupled spectrophotometric method (34) with mod-
ifications (6). Specific activity was calculated as described previously (5).
Analysis of intracellular pools of amino acids. M. smegmatis cells were grown
in minimal medium until exponential phase and split into two subcultures, and
DCS was added to a final concentration of 75 g ml1 to one of the subcultures.
After 2 h of incubation, cells were harvested at 4°C by centrifugation, washed
twice with ice-cold double-distilled water, and concentrated 50-fold. Cells were
sonicated in a salt-ice-water bath with a Vibra-Cell model VC600 sonicator
(Sonic and Materials, Inc., Danbury, Conn.) for 10 min at 80% power output and
50% duty cycle. The lysate was centrifuged at 4°C for 30 min at 30,000 	 g to
remove bacterial debris. Protein was removed from the supernatant by serial
passages through YM-10 and YM-3 Centricon concentrators (Millipore Corp.,
Bedford, Mass.). Determination of the abundance of individual amino acids was
performed at the Amino Acid Geochronology Laboratory of Northern Arizona
University (Flagstaff, Ariz.) by a reverse-phase high-performance liquid chroma-
tography (HPLC) procedure described previously (15). This procedure is able to
detect nine pairs of L- and D-amino acids in the subpicomole range. For each
sample, the area of the peak representing L-glutamate constituted 50 to 60% of
the total area. Thus, the abundance of each amino acid was calculated as the area
under the corresponding peak and expressed relative to this pool.
RESULTS
Overexpression of the M. smegmatis and M. tuberculosis ddl
genes in recombinant M. smegmatis. In previous studies, a
genomic library from a DCS-resistant mutant constructed in a
multicopy plasmid was introduced into the wild-type M. smeg-
matis strain and clones resistant to 300 g of DCS ml1 were
selected and isolated (5). Using this strategy, we did not iden-
tify a recombinant clone carrying the ddl gene. Since target
overproduction determines a drug resistance phenotype, this
outcome was unexpected. To exclude any possible bias in this
library, we also screened a M. smegmatis cosmid library in a
similar manner, but we were still unable to identify a DCS-
resistant clone carrying the ddl gene. Lowering the DCS con-
centration resulted in a high background of DCS-sensitive col-
onies. These data suggest that either the overexpression of the
ddl gene is toxic to the host or that the level of overexpression
is not sufficient to confer a selectable resistance phenotype
under the selection conditions described. To test these hypoth-
eses, the M. smegmatis and M. tuberculosis ddl genes were
amplified from genomic DNA and cloned into the E. coli-
Mycobacterium shuttle vector pMV262, carrying a kanamycin
resistance marker. Recombinant plasmids were introduced
into M. smegmatis, and kanamycin-resistant transformants
were isolated.
The M. smegmatis ddl gene was isolated from a genomic
library as described in Materials and Methods. The DNA frag-
ment containing the ddl gene coding sequence, including 190
bp of the 5 flanking region and 35 bp of the 3 flanking region,
was amplified by PCR and ligated into the EcoRI site of
pMV262 to generate pBUN250. This plasmid was electropo-
rated into M. smegmatis mc2155, yielding GPM259. Since
pMV262 is present in M. smegmatis at 5 to 10 copies (5), the
ddl gene is expected to be overexpressed in the recombinant M.
smegmatis strain due to a gene dosage effect. This was con-
firmed by primer extension analysis using total RNA isolated
from mc2155 and GPM259. Radiometric quantitation of the
primer extension bands confirmed that GPM259 overproduced
the ddl transcript by 25-fold compared to mc2155. In both
samples, two transcriptional start sites were detected, one im-
mediately upstream and another 3 nucleotides upstream of the
start codon (GTG) (Fig. 1A). Further analysis of the sequence
immediately adjacent to the start codon did not reveal any
significant RNA secondary structures, excluding the possibility
that the two bands detected were the result of premature
extension products. It has been found for the Mycobacterium
fortuitum blaF (30) and 11 streptomycete genes (27) that tran-
scription start sites are extremely close to the start codon. This
may suggest that translation initiation in both mycobacteria
and streptomycetes has less-stringent requirements for the rec-
ognition of a ribosome-binding site.
Following the same strategy, we constructed an M. smegma-
tis recombinant strain, GPM198A, carrying the plasmid
pBUN128A, a pMV262-based plasmid containing the M. tu-
berculosis ddl gene coding sequence, including 140 bp of the 5
flanking region and 130 bp of the 3 flanking region. Total
RNA isolated from GPM198A was subjected to primer exten-
sion analysis using oligonucleotides specific to either the M.
smegmatis or the M. tuberculosis ddl gene. The results revealed
that this strain overexpressed the endogenous M. smegmatis ddl
gene rather than the plasmid-carried M. tuberculosis ddl gene
(data not shown). To circumvent this problem, a different
strategy was followed. Briefly, the M. tuberculosis ddl gene was
amplified by PCR and cloned into pMV262, yielding
pBUN276. In this construct, the M. tuberculosis ddl gene is
fused in frame with the first six codons of the Mycobacterium
bovis BCG hsp60 gene and is under the control of its promoter.
Total RNA isolated from the corresponding recombinant
strain, GPM265, was subjected to primer extension analysis as
described above. In this case, the chromosomally encoded ddl
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gene in GPM265 was expressed at a level similar to the level in
wild-type mc2155 (Fig. 1A), while the episomal M. tuberculosis
ddl gene was expressed at an approximately 30-fold-higher
level than the chromosomally encoded ddl gene (Fig. 1B). The
transcriptional start site of the M. tuberculosis ddl gene located
on pBUN276 was identified as the G nucleotide located 183 bp
upstream of the start codon of the hsp60 gene, consistent with
previous observations (26). As expected, no M. tuberculosis ddl
transcript was detected from mc2155 or GPM259 total RNA.
Enzymatic characterization of M. smegmatis strains. The
overexpression of the M. smegmatis or M. tuberculosis ddl gene
was further confirmed by measuring Ddl enzyme activities. For
this, Ddl-specific activities in cell crude extracts from mc2155,
GPM259, and GPM265 were determined by the TLC-based
method described in Materials and Methods. A typical auto-
radiogram of the TLC-based Ddl enzyme assays for strain
GPM259 is shown in Fig. 2A. Ddl-specific activities in crude
extracts from GPM259 and GPM265 were about 35 and 30
times greater, respectively, than that in mc2155 extracts (Fig.
3A). These increases in Ddl activity were consistent with the
primer extension results. As a control, Alr enzyme activities
were concurrently determined by a coupled spectrophotomet-
ric method as described in Materials and Methods. As ex-
pected, cell crude extracts from mc2155, GPM259, and
GPM265 displayed similar Alr activities (Fig. 3B), indicating
that overexpression of the ddl gene is specific and does not
alter the expression of the alr gene. Furthermore, there were
no observed differences between the recombinant strains over-
producing Ddl and the wild-type strain regarding growth rate,
growth saturation density, and colony morphology, indicating
that the overexpression of the ddl gene is not toxic to the host.
Previously, David et al. (9) reported that DCS competitively
inhibits the M. tuberculosis Ddl enzyme. In this study, we per-
formed in vitro inhibition assays to determine the Ddl-specific
activities of crude extracts from mc2155, GPM259, and
GPM265 in the presence of increasing concentrations of DCS.
A typical autoradiogram of the inhibition assay for the crude
extract of GPM259 is shown in Fig. 2B. The degree of inhibi-
tion for the Ddl activities in these extracts increased propor-
tionally to the DCS concentration (Fig. 4). No statistically
significant differences between the extracts from mc2155 and
GPM259 were observed. However, though the inhibition of the
Ddl activity in GPM265 crude extract followed a similar pat-
tern, the percentage of inhibition was approximately 10%
higher at each concentration of DCS (P 
 0.02). Since the
primer extension analysis indicated that more than 95% of the
Ddl activity present in the crude extract of GPM265 is from the
expression of the M. tuberculosis ddl gene, this slight difference
may reflect a moderately higher sensitivity of the M. tubercu-
losis Ddl enzyme to DCS inhibition. In summary, these data
indicate that both M. smegmatis and M. tuberculosis Ddl en-
zymes are inhibited by DCS in a concentration-dependent
manner and provide further evidence that Ddl is a target of this
drug.
Drug susceptibilities of M. smegmatis strains. To test
whether Ddl overproduction confers a DCS resistance pheno-
type, we evaluated the susceptibilities of M. smegmatis strains
overproducing Ddl to DCS. The MICs of DCS for mc2155,
GPM259, GPM265, and GPM14 were determined (Table 2).
GPM14, overproducing Alr, is a spontaneous DCS-resistant
mutant derived from mc2155 (5). The MICs of DCS for strains
GPM259 and GPM265 (both at 150 g ml1) were twofold
greater than that for mc2155 (75 g ml1) but were lower than
that for GPM14 (300 g ml1). Thus, recombinant strains
overproducing Ddl showed increased levels of resistance to
DCS but were not as resistant as the Alr-overproducing strain
GPM14. The susceptibilities of these strains to CDA, which
interferes with the incorporation of D-alanine into the bacterial
cell wall, were also determined (Table 2). CDA, an analog of
D-alanine, was reported to target bacterial alanine racemases
and transaminases (17) and showed a synergistic effect with
DCS against M. tuberculosis (10). In this study, only the strain
overproducing Alr showed increased resistance to CDA, as
FIG. 1. Primer extension analysis of the M. smegmatis and M. tu-
berculosis ddl transcripts. Total RNA (40 g) from mc2155, GPM259,
and GPM265 was annealed with primer SMDDLPE (A) or TBDDLPE
(B) and extended as described in Materials and Methods. Lanes A, C,
G, and T display a dideoxy sequencing ladder with the corresponding
primer. Asterisks, transcriptional start sites. The putative 10 boxes
are highlighted. The start codon (GTG) for the M. smegmatis ddl gene
is boxed.
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the MIC for GPM14, 100 g ml1, is fourfold higher than
those for other strains with wild-type levels of Alr. These data
are consistent with the mode of action of CDA, which inhibits
the Alr enzyme. In addition, susceptibilities to other antimi-
crobial agents targeting cell wall biosynthesis (ethambutol and
vancomycin), RNA synthesis (rifabutin, a structural analog of
rifampin with higher antimycobacterial activity), and protein
synthesis (amikacin) of these M. smegmatis strains were iden-
tical (data not shown). The DCS resistance phenotype of the
Ddl-overproducing strains was further confirmed by plating
bacteria on solid agar containing various concentrations of
DCS. Consistent with the MIC data, GPM259 and GPM265
are more resistant to DCS than the wild-type mc2155 but less
resistant than the Alr-overproducing strain GPM14 (Fig. 5).
Furthermore, this type of intermediate level of resistance to
DCS is not related to Alr, since crude extracts from both
GPM259 and GPM265 contained a wild-type level of Alr ac-
tivity (Fig. 3B). Therefore, overproduction of the Ddl enzymes
leads to a DCS resistance phenotype in M. smegmatis. How-
ever, this level of resistance may not suffice for selection of
DCS-resistant clones by following the strategy described
above.
Construction and characterization of an Alr-Ddl-overpro-
ducing strain. It has been reported previously that a specific
type of DCS-resistant Streptococcus gordonii mutants displayed
elevated Alr and Ddl activities and that the level of resistance
FIG. 2. Autoradiograms of the TLC for typical Ddl assays. Ddl activities in crude extracts were determined as described in Materials and
Methods. (A) Linear increase in the synthesis of the D-alanine:D-alanine dipeptide at increasing amounts of GPM259 cell extract. The percentage
of conversion was defined as the percentage of the total radioactivity present in the [14C]D-Ala:D-Ala dipeptide spot. (B) Percent inhibition of
dipeptide formation (percent inhibition 
 100  100 	 [percent conversionwith DCS/percent conversionwithout DCS]) in GPM259 cell extract (8 g
of total protein) at increasing concentrations of DCS.
FIG. 3. Analysis of Dlr and Alr activities in M. smegmatis strains.
Specific activities for Ddl (A) and Alr (B) in crude extracts were
determined as described in Materials and Methods. Specific activities
are expressed as micromoles of substrate (L-alanine for Alr enzyme
assay and D-alanine for Ddl enzyme assay) per milligram per minute
(means  standard deviations of triplicate measurements).
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to DCS is higher than that for mutants with elevated Alr
activity only (22). To test the effect of the overproduction of
both Alr and Ddl in M. smegmatis on DCS susceptibility, we
introduced the multicopy plasmid pBUN250 carrying the ddl
gene into the Alr-overproducing strain GPM14. As expected,
the resulting strain, GPM260, overproduced both Alr and Ddl
as demonstrated by enzymatic characterization (Fig. 3). In
addition, the degree of inhibition of the Ddl activities in ex-
tracts from GPM260 and its parental strain, GPM14, increased
proportionally to the DCS concentration (Fig. 4). No statisti-
cally significant differences between these extracts were ob-
served (P 
 0.28). Note that the overproduction of Alr in
GPM14 and GPM260 does not alter the degree of in vitro
inhibition of the Ddl enzyme by DCS. Thus, increasing
amounts of Alr protein do not seem to affect the inhibitory
effect of DCS on Ddl activity. The susceptibilities of GPM260
to CDA, ethambutol, vancomycin, rifabutin, and amikacin
were identical to those of the parent strain, GPM14 (Table 2
and data not shown). However, GPM260, overproducing both
Alr and Ddl, was significantly more resistant to DCS than the
wild-type strain or strains overproducing only Alr or Ddl (Ta-
ble 2 and Fig. 5).
Analysis of the intracellular L- and D-alanine pools. The
incorporation of D-alanine into peptidoglycan requires the se-
quential interconversion of L- into D-alanine followed by the
formation of the D-alanine dipeptide, reactions catalyzed by
Alr and Ddl, respectively. The interplay between D-alanine
biosynthesis by Alr and its consumption by Ddl contributes to
the determination of the intracellular level of this amino acid.
Inhibition of Alr alone would decrease the intracellular pool of
D-alanine. Therefore, in live bacilli exposed to sublethal con-
centrations of DCS (near the MIC for the wild-type strain), if
Alr is inhibited to a greater extent than Ddl, a decrease in the
FIG. 4. Inhibitory effect of DCS on M. smegmatis Ddl activities.
Enzyme activities were determined in cell crude extracts from mc2155
(solid squares), GPM14 (solid triangles), GPM259 (open triangles),
GPM260 (open squares), and GPM265 (solid diamonds) in the pres-
ence of increasing concentrations of DCS. Percent inhibition was cal-
culated (percent inhibition 
 100  100 	 [SAwith DCS/SAwithout DCS];
SA, specific activity) from three independent experiments. Statistical
analysis was performed as described in Materials and Methods. The
inhibition patterns can be divided into two groups (group I, mc2155,
GPM14, GPM259, and GPM260; group II, GPM265). A significant
difference between groups was detected (P
 0.02), while no significant
differences within group I were detected (P 
 0.28).
FIG. 5. Inhibition of colony formation by DCS for various M. smeg-
matis strains. The curves were generated from data of a representative
experiment with mc2155 (solid squares), GPM2 (open squares),
GPM259 (open triangles), GPM265 (solid triangles), GPM14 (solid
diamonds), and GPM260 (open diamonds). Statistical analysis for
three independent experiments was performed as described in Mate-
rials and Methods. Susceptibilities to DCS can be divided into four
groups (group I, mc2155 and GPM2; group II, GPM259 and GPM265;
group III, GPM14; group IV, GPM260). Significant differences be-
tween groups were detected (group I versus group II, P 
 0.003; group
II versus group III, P 
 0.025; group III versus group IV, P 
 0.020),
while no significant differences within groups were detected (P 
0.881).
TABLE 2. MICs of DCS M. smegmatis strains
Strain
Phenotype MIC
a
(g ml1)
Alr Ddl CDAb DCSc
mc2155 wte wt 25.0 75.0
GPM2 wt wt 25.0 75.0
GPM259 wt Overproduced 25.0 150
GPM14 Overproduced wt 100 300
GPM260 Overproduced Overproduced 100 600
GPM265 wt Overproducedd 25.0 150
a MICs were determined in M-ADC-TW media by a microdilution method as
described in Materials and Methods.
b A chi-square test was performed for MICs obtained from at least four
independent cultures. Susceptibilities to CDA can be divided into two groups
(group I, mc2155, GPM2, GPM259, and GPM265; group II, GPM14 and
GPM260). Significant differences (P  0.001) between these two groups were
detected, while no significant differences (P  0.537) within each group were
detected.
c A chi-square test was performed for MICs obtained from at least seven
independent cultures. Susceptibilities to DCS can be divided into four groups
(group I, mc2155 and GPM2; group II, GPM259 and GPM265; group III,
GPM14; group IV, GPM260). Significant differences between these two groups
were detected (group I versus group II, P 
 0.001; group II versus group III, P

 0.001; group III versus group VI, P 
 0.008), while no significant differences
within each group were detected (group I, P 
 0.881; group II, P 
 0.893).
d More than 95% of the Ddl activity in GPM265 is due to the expression of the
episomal copy of the M. tuberculosis ddl gene (see text).
e wt, wild type.
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D-alanine pool would be expected. To test this hypothesis, we
determined the intracellular alanine pools of mc2155, GPM14,
GPM259, and GPM260 with and without DCS treatment by a
reverse-phase HPLC. This methodology allowed detection of
D- and L-alanine, L-arginine, L-asparagine/aspartate, D- and
L-glutamine/glutamate (Glx), glycine, L-isoleucine, L-leucine,
D-phenylalanine, L-serine, and D- and L-valine from samples
prepared from cell extracts as described in Materials and
Methods (Fig. 6). It was observed that the L-Glx pool was the
most abundant, probably reflecting its crucial role in nitrogen
metabolism. Moreover, this pool displayed no significant vari-
ations upon DCS treatment (P 
 0.63), so it was used as a
standard to normalize all other intracellular pools.
Comparison of the amino acid pools in each strain upon
DCS exposure revealed that this treatment had a specific effect
on the intracellular alanine pools (Fig. 7). In all strains tested,
DCS treatment led to a significant accumulation of L-alanine
(P  0.03) and a concomitant decrease of D-alanine. The
observed decrease of the D-alanine pool is statistically signifi-
cant for strains GPM259 (P 
 0.05), GPM14 (P  0.01), and
GPM260 (P  0.01). For strain mc2155, the decrease of the
D-alanine pool fell below the statistically significant level (P 

0.11). However, this strain displayed the maximum accumula-
tion of L-alanine, and the L-alanine-to-D-alanine molar ratio
increased 3.5-fold (P 
 0.01).
The intracellular pools of D- and L-alanine were also depen-
dent on the steady-state production levels of Alr and Ddl
enzymes. In cells not exposed to DCS, a twofold excess of the
L-stereoisomer was observed for strains mc2155, GMP259, and
GPM 260 (P 
 0.30) but strain GPM14 displayed almost
equimolar amounts of both isomers, a result significantly dif-
ferent from those for the rest of the strains (P 
 0.01). These
data suggest that the overproduction of Alr favors the main-
tenance of a relatively abundant pool of D-alanine. Treatment
with DCS led to the most significant changes, as observed by
comparing effects among different strains. In the wild-type
strain mc2155, an eightfold excess of L- over D-alanine was
observed. In the Alr-overproducing strain GPM14, only a
three-fold excess was observed, representing a statistically sig-
nificant difference from the wild-type strain (P 
 0.02). In
contrast, the Ddl-overproducing strains GPM259 and GPM260
displayed an 18- to 20-fold excess of L-alanine. This result
indicated that there were no significant differences between
FIG. 6. Characteristic HPLC chromatographic profiles of M. smeg-
matis intracellular amino acid pools. Intracellular amino acid pools of
M. smegmatis mc2155 untreated (A) and treated with DCS (B) were
prepared and analyzed by a reverse-phase HPLC method as described
in Materials and Methods. The synthetic amino acid L-homo-arginine
(L-hArg) served as an internal standard for quantifying the abundance
of each individual amino acid. Peaks for various amino acids are
indicated, with L- and D-alanine highlighted.
FIG. 7. Intracellular pool of alanine in M. smegmatis strains. Expo-
nentially growing M. smegmatis cells in minimal media were split into
two subcultures, and DCS was added to a final concentration of 75 g
ml1 to one of the subcultures. Cells were harvested after 2 h of
incubation, and intracellular amino acid pools were determined as
described in Materials and Methods. The intracellular pool of alanine
(full-length bars) is expressed relative to the L-glutamate pool ([Ala]/
L-Glu]). The relative abundance of each stereoisomer in the pool is
also shown by open (L-alanine) and solid (D-alanine) bars and indi-
cated in the table at the bottom. Values shown are means  standard
deviations of three independent experiments. Analysis of variance was
used to compare values for total alanine, L-alanine, and D-alanine
pools in each strain for both DCS-treated and untreated cells. Signif-
icant differences were observed for the L-alanine pools (P  0.03). For
D-alanine pools, significant differences (asterisks) were observed only
for strains GPM259 (P 
 0.05), GPM14 (P  0.01), and GPM260 (P
 0.01).
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GPM259 and GPM260 (P 
 0.80) but that these two strains
differed significantly from both the wild-type strain (P 
 0.04)
and GPM14 (P 
 0.01). Furthermore, these changes are
mostly determined by a significant reduction in the D-alanine
pool compared to the values for the wild-type strain mc2155 (P

 0.03) and GPM14 (P  0.01). These observations suggest
that, in the Ddl-overproducing strains GPM259 and GPM260,
Ddl is not significantly inhibited by DCS at concentrations that
inhibit Alr. Moreover, the inhibition of Alr by DCS was quite
effective, since the Alr-Ddl-overproducing strain GPM260 dis-
played values for both the D- and L-alanine pools similar to
those displayed by strain GPM259, with wild-type Alr levels.
DISCUSSION
In this study, we demonstrated that Ddl enzyme activities in
crude extracts were inhibited by DCS in a concentration-de-
pendent manner, similar to the effect we observed for the Alr
enzyme (5). Approximately 50% of Ddl enzyme activity is
inhibited by DCS at a concentration of 200 g/ml, while only
10 to 15% of the Ddl activity is inhibited at 50 g/ml, near the
MIC. The apparent discrepancy reflects the difference between
in vivo and in vitro conditions. In live bacilli, DCS also inhibits
Alr, resulting in a limited supply of D-Ala, which is the sub-
strate for Ddl, while in the cell-free assay, D-Ala is provided in
excess. These data confirmed that the mycobacterial Ddl en-
zyme is a target of DCS.
Overexpression of either the M. smegmatis or M. tuberculosis
ddl gene, using the same expression vectors as those used to
overexpress Alr (5), confers an intermediate level of resistance
to DCS. Furthermore, GPM260, a recombinant strain of M.
smegmatis overproducing both Alr and Ddl, was constructed
and characterized. GPM260 displayed a higher level of resis-
tance to DCS than its parent strain, GPM14, which is consis-
tent with the increased DCS resistance levels of S. gordonii
mutants with elevated Alr and Ddl activities (22). To test the
hypothesis that inhibition of Alr by DCS decreases the intra-
cellular pool of D-alanine, we compared the levels of D-alanine
pools in wild-type and recombinant M. smegmatis strains with
or without DCS treatment. The results showed that DCS treat-
ment decreased the intracellular D-alanine pools in strains with
wild-type Alr activity while the Alr-overproducing strain
GPM14 maintained a relatively abundant pool of D-alanine.
This observation is consistent with the intermediate level of
resistance to DCS of Ddl-overproducing strains. In addition,
analysis of the alanine pools in Alr-Ddl-overproducing strain
GPM260 suggests that, upon exposure to DCS, Alr is readily
inhibited. In contrast, overproduction of Alr and/or Ddl does
not have an effect on the susceptibility to vancomycin. The
increased resistance of a previously isolated M. smegmatis mu-
tant to both DCS and vancomycin (20) may underscore a
resistance mechanism different from overproduction of Alr
and/or Ddl. Regarding resistance to DCS, there has been only
one fully characterized mechanism in mycobacteria involving
overexpression of the alr gene (5). In this study, we have shown
that overexpression of the ddl gene also confers DCS resis-
tance in M. smegmatis, but at levels of resistance below those
for strains overproducing Alr. Therefore, we do not expect that
mutational changes, for example, ddl promoter-up mutations,
would play an important role in the emergence of naturally
DCS-resistant strains. The presence of a mutation(s) in the ddl
structural gene leading to DCS resistance has not been dem-
onstrated and needs further investigation.
DCS targets both Alr and Ddl enzymes, but the lethal target
for its bactericidal effect has not been identified. M. smegmatis
alr null mutants are not dependent on D-alanine for growth,
indicating that there is another pathway for D-alanine biosyn-
thesis (6). In addition, the M. smegmatis alr mutant is hyper-
susceptible to DCS, underlying the existence of another lethal
target, most likely Ddl. The DCS hypersensitivity phenotype of
the alr mutant is also consistent with the essentiality of the M.
smegmatis ddl gene, as suggested by the temperature sensitivity
phenotype of a mutant carrying a single amino acid substitu-
tion in Ddl (3). This temperature-sensitive mutant is also more
susceptible to DCS, presumably due to the low activity of the
mutated Ddl. Therefore, Ddl seems to be the lethal target of
DCS, while the inhibition of Alr by DCS further decreases the
D-alanine pool and contributes to the inhibition of Ddl. Previ-
ously, it was suggested that DCS resistance in M. tuberculosis is
primarily due to mutations in the ddl gene (9), and it was
further speculated that inhibition of Alr plays only a minor role
in the mechanism of DCS action (8). Contrary to this, our data
showed that Ddl is not significantly affected by DCS at the
concentration that inhibits Alr. Our observation suggests that
Alr overproduction contributes to the maintenance of the in-
ternal D-alanine pool, thus antagonizing the inhibition of Ddl
by DCS. For the Streptococcus faecalis enzymes, the DCS in-
hibition constants for both Alr (Ki 
 0.02 mM) and Ddl (Ki 

0.9 mM) have been determined from the purified enzymes
(19). If the Kis for the mycobacterial enzymes were to follow a
similar trend, an attractive hypothesis would be that the over-
production of a high-affinity DCS-binding target (Alr) would
protect a more fundamental and low-affinity target, probably
Ddl, from drug inhibition. In this view, the major mechanism
of resistance is the overproduction of the high-affinity but dis-
pensable target, while the bactericidal effect is due to the
inhibition of the low-affinity lethal target. Our studies do not
rule out the possibility that the bactericidal action of DCS may
result from the inhibition of a lethal target(s) other than Ddl.
Further research is necessary to assess the lethal targets in the
D-alanine branch of peptidoglycan biosynthesis in mycobacte-
ria. This information is necessary for the development of new
antimycobacterial agents targeting the D-alanine pathway.
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